Heart Doc VIP with Dr. Joel Kahn cover image

Episode 468: A Trip to the American Heart Association Meeting 2025

Heart Doc VIP with Dr. Joel Kahn

00:00

Repatha Lowers First MACE in Primary Prevention

Dr. Kahn discusses the FOURIER-type Fasalia CV trial where evolocumab reduced first cardiovascular events from 8% to 6.2% in high-risk patients without prior MI or stroke.

Play episode from 22:54
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app